MBIO Mustang Bio Inc
5,063
$0.26
$0.0102
(3.77%)
| Watchers | 5,063 |
| 52-Wk Low | $0.22 |
| 52-Wk High | $8.17 |
| Market Cap | $3.25M |
| Volume | 74,559.00 |
| 52-Wk High | $8.17 |
| 52-Wk Low | $0.22 |
Fortress Biotech Reports 2023 Financial Results and Recent Corporate HighlightsGlobe Newswire • about 1 month ago
Record consolidated net revenue of $84.5 million for full-year 2023 Fortress may receive up to four regulatory decisions on NDAs and BLAs in the next 18 months FDA accepted New Drug Application...
Share to Feed
Mustang Bio stock climbs 9% amid drug development update...
Mustang Bio stock climbs 9% amid drug development update...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is underway and expected to initiate in the...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ( Mustang or the Company ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, respectively ~70% improvement in...
WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. ( Mustang or the Company ) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical...
In a report released yesterday, Justin Zelin from BTIG maintained a Buy rating on Mustang Bio (MBIO Research Report), with a price target of $8.0...